期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

贝伐单抗治疗眼部新生血管性疾病的研究进展

Bevacizumab for treating the ocular neovascularization diseases
原文传递
导出
摘要 从分子生物学水平阐述血管内皮生长因子（VEGF）与眼部新生血管性疾病发病的关系，总结近5年来国内外应用抗VEGF药物贝伐单抗（Bevacizumab，Avastin）治疗眼部新生血管性疾病的基础和临床研究，评价其疗效及安全性。 The current paper reviews the recent studies on the relationship between vascular endo- thelial growth factor （VEGF） and ocular neovascularization diseases to explain it on the molecular biology level, and to evaluate the effects of Bevacizumab （Avatin） for treating the neovascularization diseases.
作者 吴莉爽 邱波
机构地区 广州中医药大学第二l临床学院广东省中医院眼科
出处 《国际眼科纵览》 2012年第3期199-203,共5页 International Review of Ophthalmology
关键词 新生血管形成 贝伐单抗 副作用 neovascularization Bevacizumab （Avatin） side effect
分类号 R771 [医药卫生—眼科]
  • 相关文献

参考文献27

  • 1Folkman JD, Amore PA. Blood vessel formation: what is its mo- lecular basis. Cell, 1996, 87 : 1153-1155.
  • 2Gao G, Li Y, Zhang D, et al. Unbalanced expression of VEGF and PEDF in ischemia-indueed retinal neovascularization. FEBS Lett, 2001, 489: 270-276.
  • 3Gan G, Ma J. Tipping the balance for angiogenie disorders. DrugDiscov Today, 2002, 7: 171-172.
  • 4易伟华,魏锐利,蔡季平,李玉莉.血管内皮生长因子和转化生长因子β_1在眼眶海绵状血管瘤的表达及意义[J].国际眼科杂志,2004,4(2):247-249. 被引量：6
  • 5Cross M J, Claesson-Welsh L. FGF and VEGF function in angio- genesis: signaling pathways, biological responses and therapeutic inhibit on. Trends Pharmacol Sci, 2001, 22 : 201-207.
  • 6Cohen AF, Van Bronswijk H. New medications: bevacizumab. Ned Tijdschr Geneeskd, 2006, 150: 2194-2195.
  • 7高峨嵋,徐建明.VEGF靶向药Avastin治疗实体瘤的研究进展[J].中国肿瘤临床与康复,2006,13(5):473-475. 被引量：11
  • 8Fernando NH, Hurwitz HI. Inhibition of vascular endothe-lial growth factor in the treatment of colorectal cancer. Semin Oncol, 2003, 30: 39-50.
  • 9Bakri SJ, Snyder MR, Reid JM, et al. Pharnaacokinetics of intrav- itreal bevacizumab (Avastin). Ophthalmology, 2007, 114 : 855- 859.
  • 10Barros LF, Belfort R Jr. The effects of the subconjunctival injec- tion of bevacizumab (Avastin) on angiogenesis in the rat cornea. An Acad Bras Cienc, 2007, 79: 389-394.

二级参考文献77

  • 1邹海东,张晳,许迅,汪枫桦,张世杰.上海市静安区曹家渡街道年龄相关性黄斑变性的患病率调查[J].中华眼科杂志,2005,4(1):15-19. 被引量：107
  • 2徐海峰,董晓光,王伟,陈焓.玻璃体内注射曲安奈德治疗黄斑水肿[J].中华眼底病杂志,2005,21(4):205-208. 被引量：59
  • 3Neely DE, Plager DA. Endoeyelophotoeoagulation for management of diffeicult pediatric glaucoma. J American Association for Peditric Ophthalmology and Strabismus, 2001,5 ( 4 ) : 211-229.
  • 4Adamis AP,Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina, 2005,25 (2) : 111-118.
  • 5Iliev ME,Doming D,Wolf-Schnurrbursch U,Wolf S,Sarra GM. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol, 2006,142 ( 6 ) : 1054-1056.
  • 6Lynch SS, Cheng CM. Bevacizumab for neovascular ocular diseases [ J ]. Ann Pharmacother, 2007,41 (4) :614 - 625.
  • 7Costa RA, Jorge R, Calucci D, et al. Intravitreal bevaeizumab for ehoroidal neovascularization caused by AMD ( IBeNA Study) : results of a phase 1 dose-escalation study[ J]. Invest Ophthalmol Vis Sei, 2006,47 (10) :4569 - 4578.
  • 8Kang JH, Park KA, Chung SE, et al. Retinal angiomatous proliferation and intravitreal bevacizumab injection [ J]. Korean J Ophthalmol, 2007,21 (4) :213 -215.
  • 9Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion : a short-term study [ J ]. Retina, 2006,26 ( 3 ) :279 - 284.
  • 10Iliev ME, Domig D, Wolf-Schnurrbursch U, et al. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma [ J ]. Am J Ophthalmol, 2006, 142 (6) : 1054 - 1056.

共引文献49

国际眼科纵览
2012年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部